Anticancer Metal-Based Compounds

Dear Colleagues,

This Special Issue of Biomedicines explores the latest advancements in the field of anticancer metal-based compounds. Metal-based compounds have long been recognized for their potential in cancer treatment due to their diverse chemical properties and unique mechanisms of action. This Special Issue features a collection of original research articles, mini reviews, comprehensive reviews, theoretical studies, and perspectives from leading experts in this field, providing insights into the design, synthesis, characterization, and therapeutic applications of metal-based compounds for cancer treatment.

The articles in this Special Issue cover a wide range of topics, including the following:

1. Design and Synthesis: Novel approaches for the design and synthesis of metal-based compounds with enhanced anticancer activity and reduced toxicity.
2. Mechanisms of Action: Investigations into the mechanisms of action of metal-based compounds, including their interactions with biomolecules, cellular targets, and signaling pathways involved in cancer progression.
3. Biological Evaluation: In vitro and in vivo studies evaluating the level of anticancer efficacy, pharmacokinetics, and toxicity profiles of metal-based compounds in preclinical and clinical settings.
4. Multimodal Therapies: Exploration of combination therapies involving metal-based compounds with other anticancer agents, including chemotherapy, radiotherapy, and immunotherapy, to enhance treatment outcomes and overcome drug resistance.
5. Targeted Delivery: Advances in the development of targeted delivery strategies to improve the selective accumulation of metal-based compounds within cancer cells while minimizing off-target effects on healthy tissues.
6. Clinical Translation: Translational research efforts aimed at advancing promising metal-based compounds from preclinical studies to clinical trials for the treatment of various types of cancer.

Overall, this Special Issue provides a comprehensive overview of the current state-of-the-art research on anticancer metal-based compounds and highlights their potential as promising candidates for the development of next-generation cancer therapeutics.

Dr. Manos Vlasiou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• metal-based compounds
• anticancer agents
• cancer treatment
• chemotherapy
• mechanisms of action
• targeted delivery
• drug design
• biological evaluation
• multimodal therapy
• clinical translation